ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing Deals

​​FREMONT, CA – (NewMediaWire) – July 02, 2024 – ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that the Company and its subsidiary BioFirst Corporation received a milestone payment of 10M shares of  ForSeeCon Eye Corporation’s securities to which the parties impute a value of $6 per share based on an internal valuation1 and a cash payment of $196,000 for its global licensing agreement with ForSeeCon Eye Corporation, which is for the Company’s Ophthalmology pipeline, including the medical device Vitargus® (valued at $187M, by third-party valuer) (the “Licensed Products”). ForSeeCon Eye Corporation is a private company registered in the British Virgin Islands. With this payment, the Company has now received aggregate cash payments of $296,000 from ForSeeCon and Oncox ($100,000), one of the Company’s other licensees. In addition to the cash payment, the Company has already received stocks from AiBtl (another licensee) and ForSeeCon, which the company believes are valued at $460M and $60M, respectively.2  The Company expects to receive additional stocks from OncoX that the Company believes is valued at $50M,3 up to $23.7M in cash and royalties of up to $370M from net sales from all three licensees (AiBtl, ForSeeCon, and OncoX), although such net sales cannot be guaranteed. “This milestone payment marks a significant achievement in the partnership between ABVC and ForSeeCon. It reflects ForSeeCon’s confidence in the Licensed Products and its determination to bring the Licensed Products to market if it completes the remaining clinical trials. It also underscores the progress towards the overall project objectives,” said Dr. Uttam Patil, ABVC’s Chief Executive Officer. He added, “The team is thrilled to receive this milestone payment from its valued partner and expects the remaining $6.8M soon. In addition to the milestone payment, the collaboration between ABVC and ForSeeCon will continue to work on adding more sites for the pivotal study and ramp up the momentum for further development to get Vitargus® commercialized.” “It demonstrates the strength of our collaboration and the dedication of both teams to achieving our shared goals. This milestone represents an important step forward in our project and reaffirms our commitment to delivering innovative solutions in the Ophthalmology industry,” said Jerry Chang, CEO of ForSeeCon Eye Corporation. He added, “ForSeeCon is also working on getting the Vitargus Pilot plant facility to upgrade and receive the GMP certification.” Management believes the Company’s product pipeline has excellent market potential. According to iHealthcare Analyst, Inc., the global market for retinal surgery devices is expected to reach $4.3 billion by 2029, at a CAGR of 7.7%, driven partly by the rising geriatric population worldwide.4For more information about ABVC and its subsidiaries, stay updated on the latest updates or visit https://abvcpharma.com. ABVC urges its shareholders to sign up on the Company’s website for the latest news alerts; visit https://abvcpharma.com/?page_id=17707About ABVC BioPharma & Its Industry ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. For its drug products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. The Company’s network of research institutions includes Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the Company intends to conduct global clinical trials through Phase III.Forward-Looking StatementsThis press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” … 

Related Post
Innovation Newsletter
Don't miss the most important news about Innovation. Sign up to receive them by email.


Innovation Newsletter
Don't miss the most important news about Innovation. Sign up to receive them by email.

Recent Posts

TIMES BPO Rings in the Revenue Revolution for Ambitious Businesses

Imagine a world where your phone rings not with complaints, but with eager customers ready to buy. A world where…

3 hours ago

[NEW] The 2024 Best Pokémon GO Spoofer for iPhone and Android | Tenorshare iAnyGo

NEW YORK, N.Y., July 17, 2024 (SEND2PRESS NEWSWIRE) — Tenorshare is excited to announce the launch of the 2024 edition…

12 hours ago

The Cloud Wars: A Ranking of Leading Cloud Service Providers

In the realm of digital transformation, cloud computing has emerged as a pivotal technology driving innovation across industries. As businesses…

16 hours ago

GRG PROFESSIONAL SERVICES LTD and Mindrops Merge: A New Era in Global Business Solutions

In a move that’s set to shake up the business services landscape, GRG PROFESSIONAL SERVICES LTD and Mindrops have announced…

1 day ago

More than 3,000 health care organizations recognized for commitment to high-quality cardiovascular care

​​DALLAS, July 16, 2024 — Someone in the United States dies of cardiovascular disease (CVD) every 34 seconds, on average.[1]…

2 days ago

Rascals Wins “Training Diaper Product of the Year” In 2024 Baby Innovation Awards

Annual Awards Program Recognizes Innovative Companies, Services and Products Within the Baby Care Industry Annual Awards Program Recognizes Innovative Companies,…

2 days ago


Innovation Newsletter
Don't miss the most important news about Innovation. Sign up to receive them by email.